Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 14.25 mg (equivalent: benserazide, qty 12.5 mg); levodopa, quantity: 50 mg - tablet, dispersible - excipient ingredients: magnesium stearate; pregelatinised maize starch; citric acid; microcrystalline cellulose - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - tablet, dispersible - excipient ingredients: citric acid; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: yellow beeswax; hydrogenated soya oil; soya oil; gelatin; glycerol; titanium dioxide; partially hydrogenated soya oil; iron oxide red; maize starch; sorbitol; mannitol; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - roaccutane is indicated for the treatment of severe cystic acne, and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off drug. because of significant adverse effects associated with its use, roaccutane should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - dornase alfa, quantity: 1 mg/ml - spray, solution - excipient ingredients: water for injections; calcium chloride dihydrate; sodium chloride - chronic administration of pulmozyme is indicated for the management of demonstrated respiratory complications in cystic fibrosis. continued use should depend on demonstrating a sustained benefit based on clinical response and, if able to be performed, pulmonary function tests.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - capsule, hard - excipient ingredients: indigo carmine; purified talc; gelatin; iron oxide red; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 50 mg; benserazide hydrochloride, quantity: 14.25 mg (equivalent: benserazide, qty 12.5 mg) - capsule, hard - excipient ingredients: indigo carmine; iron oxide black; magnesium stearate; microcrystalline cellulose; purified talc; titanium dioxide; povidone; mannitol; gelatin - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - atezolizumab, quantity: 840 mg - injection, concentrated - excipient ingredients: histidine; glacial acetic acid; polysorbate 20; sucrose; water for injections - early-stage non-small cell lung cancer,tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with stage ii to iiia (as per 7th edition of the uicc/ajcc staging system) nsclc whose tumours have pd-l1 expression on greater than or equal to 50% of tumour cells.,metastatic non-small cell lung cancer,tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.,tecentriq, in combination with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and carboplatin, is indicated for first-line treatment of patients with metastatic non-squamous nsclc who do not have tumour egfr or alk genomic aberrations.,tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic nsclc after prior chemotherapy. patients with egfr mutant or alk-positive nsclc should also have received targeted therapies before receiving tecentriq.,small cell lung cancer,tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (es-sclc).,urothelial carcinoma,tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who,? are considered cisplatin ineligible and whose tumours express pd-l1 (pd-l1 stained tumour-infiltrating immune cells [ic] covering greater than or equal to 5% of the tumour area), as determined by a validated test, or,? are considered ineligible for any other platinum-containing chemotherapy regardless of the level of tumour pd-l1 expression.,this indication is approved based on overall response rate and duration of response in a single-arm study. improvements in overall survival, progression-free survival, or health-related quality of life have not been established.,hepatocellular carcinoma,tecentriq, in combination with bevacizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (hcc) who have not received prior systemic therapy.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - faricimab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine; acetic acid; methionine; sodium chloride; sucrose; polysorbate 20; water for injections - vabysmo is indicated for the treatment of:,- neovascular (wet) age-related macular degeneration (namd),- diabetic macular oedema (dmo).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - baloxavir marboxil, quantity: 40 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; povidone; sodium stearylfumarate; purified talc; hypromellose; titanium dioxide - treatment of influenza,xofluza is indicated for the treatment of uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:,? otherwise healthy, or,? at high risk of developing influenza complications.,prophylaxis of influenza,xofluza is indicated for the post-exposure prophylaxis of influenza in patients aged 12 years of age and older following contact with an individual who has confirmed influenza.,vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - baloxavir marboxil, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; povidone; sodium stearylfumarate; purified talc; hypromellose; titanium dioxide - treatment of influenza,xofluza is indicated for the treatment of uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:,? otherwise healthy, or,? at high risk of developing influenza complications.,prophylaxis of influenza,xofluza is indicated for the post-exposure prophylaxis of influenza in patients aged 12 years of age and older following contact with an individual who has confirmed influenza.,vaccination is the preferred method of routine prophylaxis against infection with influenza virus.